Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $46 to $38.
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $46 to $38.